1997 Annual Report
Product Review Financials Setting
  | Financial Highlights | Financial Review |
| Management’s Report | Audit Committee’s Report |
| Independent Auditors’ Report | Financial Statements
| Notes to Financial Statements |
| Directors, Committees, and Officers |
| Corporate and Shareholder Information |
| Consolidated Income |
| Consolidated Balance Sheet |
| Consolidated Shareholder’s Equity |
| Consolidated Cash Flows |
| Segment Information | Geographic Data |
| Quarterly Data | Financial Summary |
 

  Consolidated Statement of Income
  Pfizer Inc and Subsidiary Companies

  Year ended December 31    
(millions, except per share data)   1997   1996   1995 
  • Net sales
  •  $ 12,188  $ 11,306  $ 10,021 
  • Alliance revenue
  •   316     —  
  • Total revenues
  •   12,504   11,306   10,021 
  • Costs and expenses
  •            
    • Cost of sales
      2,274   2,176   2,164 
    • Selling, informational and administrative expenses
      4,956   4,366   3,855 
    • Research and development expenses
      1,928   1,684   1,442 
    • Other deductions — net
      258   276   261 
  • Income from continuing operations before provision for
         taxes on income and minority interests
  •   3,088   2,804   2,299 
  • Provision for taxes on income
  •   865   869   738 
  • Minority interests
  •   10   6  
  • Income from continuing operations
  •   2,213   1,929   1,554 
  • Discontinued operations — net of taxes on income
  •       19 
  • Net income
  •  $ 2,213  $ 1,929  $ 1,573 

  • Earnings per common share—basic
  •            
    • Income from continuing operations
     $ 1.76  $ 1.55  $ 1.26 
    • Discontinued operations — net of taxes on income
          .02 
    • Net income
     $ 1.76  $ 1.55  $ 1.28 

  • Earnings per common share—diluted
  •            
    • Income from continuing operations
     $ 1.70  $ 1.50  $ 1.23 
    • Discontinued operations — net of taxes on income
          .02 
    • Net income
     $ 1.70  $ 1.50  $ 1.25 

  • Weighted average shares—basic
  •   1,257   1,248   1,229 
  • Weighted average shares—diluted
  •   1,303   1,288   1,259 
    See Notes to Consolidated Financial Statements which are an integral part of these statements.
      letter back top next
      Logo Imagemap
      intended for investors
      Advisory Information for Investors
      Copyright © 1997, 1998 Pfizer Inc All rights reserved.